Canaccord Genuity set a $11.00 price objective on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in a research note published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Aurinia Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, October 24th. HC Wainwright reaffirmed a buy rating and set a $12.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 15th. Vetr raised Aurinia Pharmaceuticals from a hold rating to a buy rating and set a $6.64 price target on the stock in a research report on Wednesday, September 13th. Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the company a buy rating in a research report on Friday, August 11th. Finally, BidaskClub cut Aurinia Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $10.79.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.13 on Friday. Aurinia Pharmaceuticals has a 1 year low of $2.02 and a 1 year high of $10.54.
ILLEGAL ACTIVITY WARNING: “Aurinia Pharmaceuticals Inc (AUPH) Given a $11.00 Price Target by Canaccord Genuity Analysts” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/21/aurinia-pharmaceuticals-inc-auph-given-a-11-00-price-target-by-canaccord-genuity-analysts.html.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $776,000. Morgan Stanley raised its stake in shares of Aurinia Pharmaceuticals by 11,061.7% during the 1st quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock valued at $3,273,000 after purchasing an additional 442,138 shares during the period. Creative Planning raised its stake in shares of Aurinia Pharmaceuticals by 6,470.6% during the 2nd quarter. Creative Planning now owns 164,265 shares of the biotechnology company’s stock valued at $1,007,000 after purchasing an additional 161,765 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter valued at $595,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Aurinia Pharmaceuticals by 357.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after purchasing an additional 684,816 shares during the period. Institutional investors own 27.66% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.